Brentuximab Vedotin Plus Bendamustine in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: A Meta-Analysis

被引：1
|
作者：
Abdelgawad, Hussien Ahmed H. [1 ,2 ]
Belal, Mohamed Mohamed [3 ]
Bashir, Mohamed Nabih [3 ]
Aboeldahab, Heba [4 ,5 ]
Eshun, Francis [1 ,2 ]
Otto, Mario [1 ,2 ]
Henry, Michael [1 ,2 ]
机构：
[1] Univ Arizona, Coll Med Phoenix, Dept Child Hlth, Phoenix, AZ USA
[2] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ USA
[3] Alexandria Univ, Fac Med, Alexandria, Egypt
[4] El Gomhoria Gen Hosp, Clin Res Dept, Alexandria, Egypt
[5] Alexandria Univ, Med Res Inst, Biomed Informat & Med Stat Dept, Alexandria, Egypt
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187466
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
    Zinzani, Pier Luigi
    Derenzini, Enrico
    Pellegrini, Cinzia
    Celli, Monica
    Broccoli, Alessandro
    Argnani, Lisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (05) : 681 - 683
  • [2] BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
    LaCasce, A.
    Bociek, G.
    Sawas, A.
    Caimi, P.
    Agura, E.
    Matous, J.
    Ansell, S.
    Crosswell, H.
    Islas-Ohlmayer, M.
    Behler, C.
    Cheung, E.
    Forero-Torres, A.
    Vose, J.
    O'Connor, O. A.
    Josephson, N.
    Advani, R.
    HAEMATOLOGICA, 2016, 101 : 45 - 46
  • [3] Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neerav
    BLOOD ADVANCES, 2021, 5 (24) : 5519 - 5524
  • [4] Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma
    Picardi, M.
    Della Pepa, R.
    Giordano, C.
    Pugliese, N.
    Mortaruolo, C.
    Trastulli, F.
    Rascato, M. G.
    Cappuccio, I
    Raimondo, M.
    Memoli, M.
    Monteverde, M.
    Mascolo, M.
    Pane, F.
    BLOOD ADVANCES, 2019, 3 (09) : 1546 - 1552
  • [5] Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis
    Forlenza, Christopher J.
    Gulati, Nitya
    Mauguen, Audrey
    Absalon, Michael J.
    Castellino, Sharon M.
    Franklin, Anna
    Keller, Frank G.
    Shukla, Neal
    BLOOD, 2020, 136
  • [6] Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients
    Ulu, Bahar Uncu
    Dal, Mehmet Sinan
    Hindilerden, Ipek Yonal
    Akay, Olga Meltem
    Mehtap, Ozgur
    Buyukkurt, Nurhilal
    Hindilerden, Fehmi
    Gunes, Ahmet Kursad
    Yigenoglu, Tugce Nur
    Basci, Semih
    Cakar, Merih Kizil
    Acik, Didar Yanardag
    Korkmaz, Serdal
    Ulas, Turgay
    Ozet, Gulsum
    Ferhanoglu, Burhan
    Nalcaci, Meliha
    Altuntas, Fevzi
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (03) : 190 - 198
  • [7] Is there a place for the combination of brentuximab vedotin and bendamustine in treatment of patients with relapsed/refractory Hodgkin lymphoma?
    Chen, Robert W.
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (11)
  • [8] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
    Mei, Matthew
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Armenian, Saro
    Chen, Robert
    Rosen, Steven
    Forman, Stephen
    Popplewell, Leslie
    Kwak, Larry
    Martin, Peter
    Maddocks, Kami
    Bond, David
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
  • [9] Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
    LaCasce, Ann S.
    Bociek, Gregory
    Sawas, Ahmed
    Caimi, Paolo F.
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen
    Crosswell, Howland
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Advani, Ranjana
    BLOOD, 2015, 126 (23)
  • [10] Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
    LaCasce, Ann S.
    Bociek, R. Gregory
    Sawas, Ahmed
    Caimi, Paolo
    Agura, Edward
    Matous, Jeffrey
    Ansell, Stephen M.
    Crosswell, Howland E.
    Islas-Ohlmayer, Miguel
    Behler, Caroline
    Cheung, Eric
    Forero-Torres, Andres
    Vose, Julie
    O'Connor, Owen A.
    Josephson, Neil
    Wang, Yinghui
    Advani, Ranjana
    BLOOD, 2018, 132 (01) : 40 - 48
12345